Cabaletta Bio, Inc.

CABA

Cabaletta Bio, Inc.

CABA

Insider Sentiment (TTM):

Last Purchase:2026-01-21Last Sale:2024-01-19Shares Purchased (TTM):132,073Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:72,525,170Shares Outstanding:112,025,474Institutional Ownership Pct.:64.74%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	225	117	83	60	146	132	164	171	179	175	193	116
Assets Current
Assets Current	231	122	139	165	198	135	167	186	206	227	244	166
Short Term Investments	0	0	51	100	49	-	0	12	25	49	48	49
Prepaid Expense And Other Assets Current	6	6	5	5	4	3	3	3	3	4	3	2
Property Plant And Equipment Net	1	2	2	2	2	3	3	3	3	3	3	2
Finance Lease Right Of Use Asset	-	17	16	16	17	20	7	-	-	-	0	-
Operating Lease Right Of Use Asset	6	2	3	4	5	5	6	14	6	8	5	4
Other Assets Noncurrent	6	5	5	4	3	2	2	2	2	2	2	1
Assets	257	148	165	190	225	165	185	204	217	240	254	173
Liabilities And Stockhold…
Accounts Payable Current	6	6	7	8	7	6	5	2	4	6	5	4
Liabilities Current
Finance Lease Liability Current	-	21	21	18	16	15	6	-	-	-	0	-
Liabilities Current	40	42	50	46	42	34	27	23	18	18	16	11
Operating Lease Liability Current	4	2	3	4	4	4	4	8	7	7	4	3
Finance Lease Liability Noncurrent	-	3	3	5	4	8	3	-	-	-	0	-
Operating Lease Liability Noncurrent	-	-	0	0	1	1	2	7	0	1	1	2
Liabilities	46	45	53	50	46	44	33	30	18	19	17	12
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital Common Stock	822	664	629	614	609	507	501	491	485	480	469	373
Stockholders Equity	211	103	112	139	178	122	152	174	200	222	236	161
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	-	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-611	-560	-517	-475	-430	-385	-349	-317	-286	-258	-233	-212
Liabilities And Stockholders Equity	257	148	165	190	225	165	185	204	217	240	254	173
Voting Common Stock	-	0	-	0	-6	6	-	-1	1	0	-	-3
Nonvoting Common Stock	-	0	-	0	-6	6	-	-1	1	0	-	0
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	150	150	150	150	150	150	150
Common Stock Shares Issued	-	-	100	96	91	-	51	49	48	48	48	42
Shares Outstanding	-	-	100	96	91	-	51	49	48	48	48	42

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-9.97%	-11.63%	-24.65%	-	-	-	-	-	-	-	-	-
2025	37.02%	-9.94%	-20.44%	0.00%	62.76%	70.34%	4.94%	-9.05%	5.76%	21.99%	17.38%	6.74%
2024	-16.94%	-44.44%	-47.12%	40.40%	6.23%	-2.49%	-12.83%	-36.51%	-36.77%	-8.30%	26.35%	29.24%
2023	-	-	-	-	-	-	-8.56%	29.57%	27.17%	-2.91%	-35.80%	-39.91%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.79	2.95	2.77	3.60	4.78	3.96	6.15	8.11	11.52	12.66	15.29	15.65
Quick Ratio	5.64	2.81	2.66	3.50	4.69	3.88	6.05	8.00	11.35	12.46	15.08	15.49
Working Capital	191.12M	80.81M	88.72M	118.83M	156.87M	100.61M	139.59M	162.63M	188.36M	209.51M	228.50M	155.56M
Leverage & Debt
Debt to Equity	0.22	0.43	0.47	0.36	0.26	0.36	0.21	0.17	0.09	0.08	0.07	0.08
Interest Coverage TTM	-80.94	-76.47	-85.95	-74.38	-92.92	-128.83	-167.30	-	-	-	-	-
Debt Ratio	0.18	0.30	0.32	0.27	0.20	0.26	0.18	0.15	0.08	0.08	0.07	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.20	-1.57	-	-	-2.33	-2.50	-	-	-	-	-	-
Free Cash Flow Per Share TTM	-0.95	-1.29	-1.33	-0.93	-1.23	-1.92	-1.78	-133.80	-64.78	-56.55	-46.43	-21.34
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	25.67%	38.39%	44.87%	52.19%	60.35%	64.91%	71.21%	66.71%	56.60%	37.55%	27.75%	22.10%
EPS Growth (1Y)	-48.56%	-37.31%	-26.84%	-99.01%	-96.97%	-96.20%	-96.06%	526.09%	453.77%	386.41%	549.87%	1,410.36%
Valuation Metrics
P/E TTM	-2.59	-1.72	-1.31	-1.42	-0.65	-0.55	-0.99	-0.03	-0.10	-0.26	-0.39	-0.57
P/B TTM	2.23	2.92	1.96	1.62	0.53	0.58	0.76	0.02	0.04	0.09	0.11	0.22
Market Cap	470.11M	301.35M	220.05M	225.26M	94.05M	70.28M	115.19M	2.95M	8.74M	19.93M	26.51M	35.70M
Enterprise Value	245.01M	208.68M	160.70M	187.21M	-31.23M	-38.24M	-39.55M	-167.66M	-169.88M	-155.37M	-166.72M	-79.80M
Calculated Values
Free Cash Flow TTM	-143.24M	-144.53M	-133.56M	-89.92M	-75.91M	-97.22M	-90.43M	-83.57M	-75.66M	-66.05M	-54.24M	-50.05M
Net Debt	-225.10M	-92.67M	-59.35M	-38.05M	-125.29M	-108.52M	-154.73M	-170.61M	-178.61M	-175.29M	-193.24M	-115.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-21Purchase

Owner: Gerard, Michael

Title: General Counsel

Shares: 6,600

Price/Share: $2.27

Value: $14,982.00

Shares Owned: 6,600

Relationship: Officer

Ownership: Direct

2026-01-21Purchase

Owner: Gavel, Steve

Title: Chief Commercial Officer

Shares: 22,170

Price/Share: $2.27

Value: $50,325.90

Shares Owned: 22,170

Relationship: Officer

Ownership: Direct

2026-01-21Purchase

Owner: Chang, David J.

Title: Chief Medical Officer

Shares: 8,800

Price/Share: $2.26

Value: $19,888.00

Shares Owned: 8,800

Relationship: Officer

Ownership: Direct

2026-01-21Purchase

Owner: Simon, Mark

Title: -

Shares: 11,061

Price/Share: $2.28

Value: $25,219.08

Shares Owned: 147,205

Relationship: Director

Ownership: Direct

2026-01-21Purchase

Owner: Tomasello, Shawn

Title: -

Shares: 22,725

Price/Share: $2.21

Value: $50,222.25

Shares Owned: 22,725

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-21	Gerard, Michael	Officer	General Counsel	Direct	Purchase	6,600	2.27	$14,982.00	6,600	4
2026-01-21	Gavel, Steve	Officer	Chief Commercial Officer	Direct	Purchase	22,170	2.27	$50,325.90	22,170	4
2026-01-21	Chang, David J.	Officer	Chief Medical Officer	Direct	Purchase	8,800	2.26	$19,888.00	8,800	4
2026-01-21	Simon, Mark	Director	-	Direct	Purchase	11,061	2.28	$25,219.08	147,205	4
2026-01-21	Tomasello, Shawn	Director	-	Indirect	Purchase	22,725	2.21	$50,222.25	22,725	4
2026-01-21	Bollard, Catherine	Director	-	Direct	Purchase	4,405	2.27	$9,999.35	5,405	4
2026-01-21	Nichtberger, Steven	Director,Officer	President & CEO	Direct	Purchase	45,000	2.24	$100,800.00	1,031,483	4
2026-01-21	Binder, Gwendolyn	Officer	President, Science & Tech.	Direct	Purchase	11,312	2.19	$24,773.28	31,312	4
2024-01-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	19.93	$219,230.00	20,000	4
2023-12-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	21.99	$241,890.00	20,000	4
2023-11-20	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	17.70	$194,700.00	20,000	4
2023-10-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	13.80	$151,800.00	20,000	4
2023-09-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	18.00	$198,000.00	20,000	4
2023-08-21	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	13.62	$149,820.00	20,000	4
2023-07-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	13.96	$153,560.00	20,000	4
2023-06-20	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	11,000	12.99	$142,890.00	20,000	4
2023-05-19	Binder, Gwendolyn	Officer	See Remarks	Direct	Sale	22,000	11.81	$259,820.00	20,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

64.74%

Inst. Shares: 72,525,170

Shares Outstanding: 112,025,474

2025-12-31

57.99%

Inst. Shares: 64,965,754

Shares Outstanding: 112,025,474

2025-09-30

61.66%

Inst. Shares: 59,358,898

Shares Outstanding: 96,265,204

2025-06-30

125.21%

Inst. Shares: 63,535,654

Shares Outstanding: 50,743,101

2025-03-31

61.00%

Inst. Shares: 30,953,255

Shares Outstanding: 50,743,101

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	72,525,170	112,025,474	64.74%
2025-12-31	64,965,754	112,025,474	57.99%
2025-09-30	59,358,898	96,265,204	61.66%
2025-06-30	63,535,654	50,743,101	125.21%
2025-03-31	30,953,255	50,743,101	61.00%
2024-12-31	33,122,043	50,743,101	65.27%
2024-09-30	43,436,583	624,574	-
2024-06-30	46,206,882	1,168,054	-
2024-03-31	47,157,176	1,168,054	-
2023-12-31	45,989,951	1,168,054	-
2023-09-30	40,778,578	2,345,592	-
2023-06-30	35,747,343	4,130,442	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cabaletta Bio, Inc. (CABA) — SEC Financial Statements & Analysis

Cabaletta Bio, Inc. (CABA) is a biological products, (no diagnostic substances) company, incorporated in DE. Cabaletta Bio, Inc. trades on Nasdaq as: CABA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cabaletta Bio, Inc. reported a Debt-to-Equity ratio of 0.22x, a Price-to-Book (P/B) ratio of 2.23x (TTM), at a market cap of $470.11M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.22x
P/B TTM: 2.23x
Market Cap: $470.11M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cabaletta Bio, Inc. in?

Cabaletta Bio, Inc. (CABA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CABA's market cap?

Cabaletta Bio, Inc. (CABA) has a market capitalization of $470.11M as of 2026-06-30.

What exchange does CABA trade on?

Cabaletta Bio, Inc. (CABA) trades on the Nasdaq.

Where is Cabaletta Bio, Inc. incorporated?

Cabaletta Bio, Inc. is incorporated in DE.